中药联合康柏西普及激光治疗RVO-ME的临床观察

Clinical Observation of Traditional Chinese Medicine Combined with Kangberxipu Laser in the Treatment of RVO-ME

目的 深入分析视网膜静脉阻塞(RVO)继发黄斑水肿(ME)采用散肿汤联合康柏西普及激光治疗的临床效果。方法 研究时间为2019年1月1日-2021年12月1日,研究对象选择在广东省阳春市人民医院治疗视网膜静脉阻塞继发黄斑水肿(RVO-ME)的40例患者,按照随机法分成两组,将接受单独康柏西普及激光治疗的20例患者纳入对照组,另外接受散肿汤联合康柏西普及激光治疗的20例患者作为观察组,统计两组疗效,对比两组患者的最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT),统计两组不良反应发生率。结果 治疗后,得出结论如下:(1)观察组患者的BCVA情况明显优于对照组,两组数据比较有统计学意义(P<0.05);(2)观察组患者的CMT明显比对照组CMT变薄,两组数据比较有统计学意义(P<0.05);(3)观察组疗效高于对照组(P<0.05)。结论 RVO-ME采用散肿汤联合康柏西普及激光治疗后,视力明显改善,在很大程度上缓解ME情况,疗效显著,是一项值得积极推广的应用。

Objective To deeply analyze the clinical effect of Sanzhong Decoction combined with Conbercepr Laser in the treatment of macular edema(ME) secondary to retinal vein occlusion(RVO).Methods The study period was from January 1, 2019 to December 1, 2021. The research selected 40patients with macular edema secondary to retinal vein occlusion(RVO-ME) in our hospital and were randomly divided into two groups. Twenty patients who received laser treatment with Conbercept alone were included in the control group, and another 20 patients who received Sanzhong Decoction combined with laser treatment with Conbercept were selected as the observation group. BCVA, foveal retinal thickness(CMT), and the incidence of adverse reactions in the two groups were compared.Results After treatment, the following conclusions were drawn:(1) The BCVA of the observation group was significantly better than that of the control group, and the data between the two groups was statistically significant(P<0.05);(2) The CMT of the observation group was significantly higher than that of the control group. The CMT in the group became thinner, and the data between the two groups was statistically significant(P<0.05);(3) There were no adverse events in the two groups. Conclusion After RVO-ME is treated with Sanzhong Decoction combined with Conbercepr Laser, the visual acuity is obviously improved, ME is relieved to a large extent, and the curative effect is significant. It is an application worthy of active promotion.